Tremfya Archives -

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment

NICE makes J&J’s Tremfya more accessible in England and Wales

https://pharmaphorum.com/news/nice-makes-jjs-tremfya-more-accessible-in-england-and-wales/

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23

J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay

https://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication,

J&J filing aims Tremfya at crowded psoriatic arthritis market

https://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/

Tremfya